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Over the last three decades, trends in endometrial cancer
incidence have been heterogeneous in various developed
areas of the world. In North America, endometrial cancer
incidence tended to rise from the early 1960's to the mid
1970's, but flattened off or declined from the early 1980's
onwards (Jick et al., 1980; Walker & Jick, 1980). Con-
versely, incidence was still increasing in the early 1980's in
Denmark (Ewertz & Jensen, 1984) and in most other cancer
registration areas in Europe (Parazzini et al.-, 1991), although
some reversal of trends has been observed over more recent
periods in Britain (Villard & Murphy, 1990), East Germany
(Nischan & Ebeling, 1991) and Sweden (Persson et al., 1990)
in women before age 55. This has been discussed in terms of
a favourable impact of oral contraceptives on endometrial
cancer rates for these younger cohorts of women (Villard &
Murphy, 1990; Nischan & Ebeling, 1991; Persson et al.,
1990).
To provide further documentation on the descriptive
epidemiology of endometrial cancer, we present here
incidence and survival data from the Cancer Registry of the
Canton of Vaud, Switzerland. In this cancer registration
area, incidence rates were among the highest on a European
scale (Levi et al., 1989).
The data were abstracted from the Vaud Cancer Registry
file (Levi, 1987), which includes incident cases of malignant
neoplasms in the canton, whose population, according to the
1980 Census, was about 530,000 inhabitants. The registry is
tumour-based and multiple primaries occurring in the same
person are entered separately. Notification is based on a
voluntary agreement between the recording medical institu-
tions of the Canton and the Registry. All hospitals,
pathological laboratories and most practitioners are asked to
report all new or past cases of cancer. The main source of
notification is the Cantonal University Pathological Depart-
ment of Lausanne which performs the majority of his-
tological examinations for the population covered by the
Registry. Most cases are registered repeatedly and from
different institutions, thus improving completeness and
accuracy of registration. Further checks for completeness are
made with neighbouring cancer Registries. Over 80% of the
cases are registered within one month since diagnosis.
Information collected comprises general demographic char-
acteristics of each case (age, sex, municipality of residence),
site and histological type of the tumour according to stan-
dard International Classification of Diseases for Oncology
(ICD-O), and time of diagnostic confirmation.
The present report includes 909 endometrial cancers
registered from 1974 to 1988. Histological confirmation was
obtained for 98% of the series, and tumours discovered from
death certificate alone accounted for about I% (n = 12)
across the period considered. Age-specific and age-stan-
dardised rates were computed using the direct method on the
basis of the world standard population.
Information on survival is integrated from mortality statis-
tics into the incidence datafile and, for patients who are
'apparently alive', through an active follow-up based on
verification ofvital status from registries ofcurrent residence.
The vital status of each case has been verified up to June 30,
1989. Thus, this is one of the few European cancer registries
that provides population-based survival data (Levi et al.,
1992).
Table I gives the trends in age-standardised (world) rates
in two separate age groups. In women aged 30-59, endo-
metrial cancer incidence steadily declined by about 40%,
from 20.0/100,000 in 1974-78 to 12.6/100,000 in 1984-88.
At older age (>,60 years) no material change in incidence
was observed.
Figure 1 presents, on a logarithmic scale, the age curve
from 30-39 to 70-79 years in three subsequent calendar
quinquennia (1974-78, 1979-83 and 1984-88). The fall in
rates was substantial at younger age (i.e., under 50 years,
particularly over the last calendar quinquennium) and in
middle age (from 50 to 59 years), but no clear pattern of
trends was apparent above age 60.
Figure 2 shows survival rates from endometrial cancer in
the same three subsequent 5-year calendar periods. Five-year
relative survival increased from 0.72 in 1974-78 to 0.77 in
1984-88, and there was a consistent trend of improved sur-
vival over more recent calendar periods.
Thus, there are two main findings emerging from this
analysis of endometrial cancer trends in the Swiss Canton of
Vaud: a decline in incidence, and some improvement (or, in
any case, no evidence of worsening) in survival. Trends in
survival data are important in order to understand and inter-
pret changes in incidence, since endometrial cancers related
to oestrogen replacement treatment have a better prognosis
(Robboy & Bradley, 1979), and in the United States a sub-
stantial decline in incidence following the fall in oestrogen
use has been followed by a worsening in survival rates
(Anonymous, 1991).
Following this line of reasoning, changes in pattern of
Table I Age-standardised (world) incidence rates for endometrial
cancerin two broad age groups. Cancer Registry ofVaud, Switzerland,
1974-1988
Incidence rates/100,000 women at age:
Calendarperiod 30-59 years >60 years All ages
1974-78 20.0 (108)- 72.2 (203) 14.6 (313)
1979-83 17.0 (95) 72.4 (221) 13.4 (316)
1984-88 12.6 (72) 69.0 (208) 11.7 (280)
Average annual population
(x 1000) 108.2 34.2 142.0
'Number of cases is given in parentheses.
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Figure 1 Trends in age-specific (decennial age groups) endomet-
rial cancer incidence in the Canton of Vaud, from 1974 to 1988.
oestrogen replacement use are unlikely to totally explain the
declines in endometrial cancer incidence. In the late 1980's,
ever use of oestrogen replacement treatment was reported
by about 20% of women in peri-menopausal age (Levi et al.,
1991). The proportion of ever (mainly past) users aged 60
to 69 was similar (22%), thus indicating that no major
change in the prevalence of oestrogen replacement treatment
was observed in subsequent generations of Swiss women over
the last two decades. Sales data were available from 1985
onwards (IMS-Switzerland, personal communication), and
show a modest decline of unopposed oestrogen use.
Moreover, there was an appreciable increase in the use
of combined oestrogen-progestin treatment, which may
have favourably influenced trends in endometrial cancer
incidence.
Oral contraceptives started to be used in Switzerland in the
late 1960's, and their prevalence of use increased up to the
late 1970's. In the late 1980's, the proportion of current users
was 25% of women aged 20 to 44 (Levi et al., 1987). In a
case-control study conducted in the Canton of Vaud, ever
use of oral contraceptives was reported by approximately
60% of women below age 50, and 30% of those aged 50 to
59, and, assuming a protection for ever use of 50% (Levi et
al., 1991), this would imply (Bruzzi et al., 1985) an about
20% reduction in incidence under age 60 (i.e., 30% reduction
under age 50, and 15% between 50 and 59), whereas rates
under age 60 declined by 40%.
There is no reliable information in trends of obesity - the
other major established risk factor for endometrial cancer
(La Vecchia et al., 1982) - or on the proportion of women
with hysterectomy, but it is clear from the data presented
that, besides a relevant role of oral contraceptives, and a
changed pattern of menopausal replacement treatment use,
only a complex of several factors can explain the favourable
endometrial cancer trends reported in this Swiss population
over the last two decades.
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Figure 2 Relative survival of 909 endometrial cancers according to period of diagnosis. Cancer Registry of Vaud, Switzerland,
1974-88.
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